LOBEF (Lobe Sciences) ROCE %: -311.36% (As of Feb. 2026)


What is Lobe Sciences ROCE %?

Lobe Sciences LOBEF ROCE % is -311.36% as of Feb. 2026. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lobe Sciences's annualized ROCE % for the quarter that ended in Feb. 2026 was -311.36%.

Lobe Sciences  (OTCPK:LOBEF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lobe Sciences ROCE % Related Terms

Lobe Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences ROCE % Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.66 -203.82 -2,930.97 0.00 -272.10

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -260.01 -156.48 -110.66 -311.36

Lobe Sciences ROCE % Calculation

Lobe Sciences's annualized ROCE % for the fiscal year that ended in Aug. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=-3.091/( ( (0.19 - 1.66) + (5.5 - 1.758) )/ 2 )
=-3.091/( (-1.47+3.742)/ 2 )
=-3.091/1.136
=-272.10 %

Lobe Sciences's ROCE % of for the quarter that ended in Feb. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=-6.948/( ( (5.04 - 2.16) + (3.703 - 2.12) )/ 2 )
=-6.948/( ( 2.88 + 1.583 )/ 2 )
=-6.948/2.2315
=-311.36 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -311.36% mean?
Lobe Sciences (LOBEF) has a ROCE % of -311.36% as of Feb. 2026.
Is Lobe Sciences' ROCE % too high?
Lobe Sciences' current ROCE % is -311.36%.
How does Lobe Sciences' ROCE % compare to VRTX and REGN?
Lobe Sciences' ROCE % of -311.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Lobe Sciences's current ROCE % is -311.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current ROCE % of -311.36%. The current ROCE % is -311.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current ROCE % is -311.36% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.